Poster Sessions

Poster Session A: Cancers of the Esophagus and Stomach
Thursday, January 17, 2019 11:30 AM- 1:00 PM and 5:30 PM- 6:30 PM

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
Thursday, January 17, 2019 11:30 AM- 1:00 PM and 5:30 PM- 6:30 PM

Posters by Topic
Prevention, Diagnosis, and Screening: Poster Boards D19-F12
Multidisciplinary Treatment: Poster Boards D11-D18, H3-N4
Translational Research: Poster Boards F13-H2
Trials in Progress: Poster Boards N5-N16

BOARD D11
Abstract 62: First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).
First Author: Yelena Janjigian, MD


BOARD D12
Abstract 2: Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
First Author: Takashi Kojima, MD


BOARD D13
Abstract 3: Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS).
First Author: David Ilson, MD, PhD


BOARD D14
Abstract 4: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).
First Author: Manish Shah, MD, FASCO


BOARD D15
Abstract 5: Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.
First Author: Hirva Mamdani, MD


BOARD D16
Abstract 6: FOLFOX versus POF (Paclitaxel plus FOLFOX) versus IP PAC (Intraperitoneal Paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.
First Author: Rongbo Lin


BOARD D17
Abstract 7: Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502).
First Author: Ken Kato, MD, PhD


BOARD D18
Abstract 8: Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.
First Author: Yoon-Koo Kang, MD, PhD


BOARD D19
Abstract 9: Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy.
First Author: Ik Hyun Jo, MD


BOARD D20
Abstract 10: The difference of the gut microbiota of gastric cancer in relation to Helicobacter pylori negativity and positivity.
First Author: Mijin Seol


BOARD E1
Abstract 11: Tislelizumab in combination with chemotherapy in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer: Results from one cohort of an ongoing phase 2 study.
First Author: Yu-Xian Bai, MD


BOARD E2
Abstract 12: Prognostic value of DNA repair gene based on stratification of gastric cancer.
First Author: Jinjia Chang


BOARD E3
Abstract 13: M1a disease should be reconsidered in esophageal cancer staging system from the perspective of treatment response and survival after definitive concurrent chemoradiotherapy.
First Author: Tae Ryong Chung, MD


BOARD E4
Abstract 14: Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study.
First Author: Nong Xu


BOARD E5
Abstract 15: Reliability of endoscopic biopsy compared with endoscopic submucosal dissection histopathologic diagnosis.
First Author: Tae Ho Kim


BOARD E6
Abstract 16: Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
First Author: Ugur Sahin


BOARD E7
Abstract 17: Feasibility study of diet counseling (DC) with oral nutritional supplements (ONS) for advanced esophageal and gastric cancer during chemotherapy (CT) or chemoradiotherapy (CRT): First report of ONS compliance from a prospective randomized controlled clinical study (DiCON study).
First Author: Yukiko Izawa, MHSc


BOARD E8
Abstract 18: Incidence and prognosis of multiple organ involvement at gastric MALT lymphoma.
First Author: Tae Hun Kwon


BOARD E9
Abstract 19: Impact of intramuscular fat accumulation on survival in stage II/III gastric cancer.
First Author: Yuhei Waki, MD.


BOARD E10
Abstract 20: Incidence of metachronous gastric neoplasia after endoscopic submucosal dissection for gastric dysplasia.
First Author: Jae Kim


BOARD E11
Abstract 21: Characteristics and epidemiology of gastric cancer in Korea: Disparity in sex and age according to histologic classification.
First Author: Dongwoo Kim, MD


BOARD E12
Abstract 22: Gastric cancer staging in the era of neoadjuvant therapy and its prognostic implications.
First Author: Gina Kim, MD


BOARD E13
Abstract 23: Utilizing cultural and ethnic variables in a survey to identify individuals at high risk for gastric cancer.
First Author: Ian Solsky


BOARD E14
Abstract 24: The gastric cancer survivorship experience: A global perspective.
First Author: Martha Raymond, MA


BOARD E15
Abstract 25: Association of socioeconomic status with incidence and outcomes of gastric cancer in a Michigan cohort.
First Author: Lilit Karapetyan, MD


BOARD E16
Abstract 26: T-cell–inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).
First Author: Torben Steiniche


BOARD E17
Abstract 27: Prognosis of gastric dysplasia after complete resection with endoscopic procedures.
First Author: Junseok Park


BOARD E18
Abstract 28: Disparities associated with the receipt of palliative care in patients with metastatic gastric cancer.
First Author: Subhadeep Paul, BA


BOARD E19
Abstract 29: Single-cell analysis of immune-microenvironment and immune-tumor interaction in human gastric cancers.
First Author: Michele Goh


BOARD E20
Abstract 30: Review of updated gastric cancer disease management data in the Colombian national administrative cancer registry.
First Author: Robert Hsu, MD, MS


BOARD F1
Abstract 31: Comparison of clinical and pathologic staging in esophageal cancer.
First Author: Anthony Scholer, MD, M.BS


BOARD F2
Abstract 32: Surveillance for locally advanced esophageal and gastroesophageal junction (GEJ) cancers: Patterns of recurrence and methods of detection.
First Author: Jubin Matloubieh, BM


BOARD F3
Abstract 33: Lower risk of gastric atrophy and intestinal metaplasia in MALT lymphoma patients despite of h. pylori infection.
First Author: San Min Lee, MD


BOARD F4
Abstract 34: The association of novel recurrent in-frame gene fusions with prognosis of diffuse gastric cancer.
First Author: Hark Kim, MD


BOARD F5
Abstract 35: Effectiveness of laparoscopic surgery in patients with large gastric GIST (diameter > 5cm).
First Author: Fei Li


BOARD F6
Abstract 36: Adjuvant therapy is associated with improved survival in pT1N1 gastric cancer in a heterogeneous western patient population.
First Author: Matthew Porembka, MD


BOARD F7
Abstract 37: The Esophageal Online Patient Reported Outcomes (EsO-PRO) Questionnaire: Formal implementation and assessment of a combined clinical and research data collection tool.
First Author: Shirley Jiang, BHSc


BOARD F8
Abstract 38: Prospective comparative study of endoscopic ultrasonography-guided fine-needle biopsy and unroofing biopsy.
First Author: Sung Kwan Shin, MD


BOARD F9
Abstract 39: Preoperative factors predictive of pathologic upstaging in clinical stage I gastric cancer patients.
First Author: Hayavadhan Thuppal, MD


BOARD F10
Abstract 40: Incidence of gastroesophageal junction cancer continues to rise: Analysis of Surveillance, Epidemiology, and End Results (SEER) database.
First Author: Michael Bartel, MD


BOARD F12
Abstract 42: The association of mutant allele frequency of TP53 with response of chemotherapy in advanced gastric cancer patients.
First Author: Shu Zhang, MD


BOARD F13
Abstract 43: DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.
First Author: Raghav Sundar, MBBS


BOARD F14
Abstract 44: MSI-low is an intermediate type between MSI-high and MSS in esophagogastric junction adenocarcinoma.
First Author: Yu Imamura, FACS, MD, PhD


BOARD F15
Abstract 45: Genomic profile of gastric cancer in the United States versus East Asia.
First Author: Gregory Gilmore, DO


BOARD F16
Abstract 46: Association between sarcopenia and gastric carcinogenesis: A health check-up cohort study.
First Author: Young min Kim, M.D.


BOARD F17
Abstract 47: Effect of surgical approach on node harvest in gastrectomy: Analysis of the National Cancer Database.
First Author: Michael Watson, MD


BOARD F18
Abstract 48: Lymphocyte-to-C-reactive protein ratio and score are clinically feasible biomarker in gastric cancer patients.
First Author: Yoshinaga Okugawa, MD, PhD


BOARD F19
Abstract 49: Expression patterns of PD-L1 and other immune checkpoint molecules in gastric cancer.
First Author: Kenichi Nakamura, M.D, Ph.D.


BOARD F20
Abstract 50: Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma.
First Author: Laila Babar, MD


BOARD G1
Abstract 51: Real-world fusion landscape in advanced Chinese gastric cancer using next generation sequencing: A multicenter study.
First Author: Rongbo Lin


BOARD G2
Abstract 52: Prediction of peritoneal recurrences of gastric cancer by qPCR analysis of peritoneal lavage fluids.
First Author: Koki Nakanishi, MD


BOARD G3
Abstract 53: Phase Ib study of andecaliximab (GS-5745, ADX) in combination with S-1+platinum chemotherapy in Japanese subjects with advanced gastric or GEJ adenocarcinoma.
First Author: Kei Muro, MD


BOARD G4
Abstract 54: Activation of central/effector memory T cells in advanced gastric cancer patients treated with antiprogrammed death-1 antibody.
First Author: Hirofumi Ohmura, MD


BOARD G5
Abstract 55: The safety assessment of robotic versus laparoscopic gastrectomy for gastric cancer using a propensity score matching method.
First Author: Rie Makuuchi, MD, PhD


BOARD G6
Abstract 56: Development of a liquid-biopsy-based technique for the supplementary diagnosis of highly advanced lymph node metastasis in patients with locally advanced gastric cancer.
First Author: Takashi Oshima, MD, PhD


BOARD G7
Abstract 57: Clinicopathological characteristics of patients with gastrointestinal stromal tumor according to progranulin expression.
First Author: Dong-Hoe Koo, MD, PhD


BOARD G8
Abstract 58: Comparison of HER2 expression by immunohistochemistry and HER2 copy number by digital PCR in tumor tissue during treatment with trastuzumab in the prospective cohort of metastatic HER2-positive gastric cancer patients.
First Author: Naoki Takahashi, PhD


BOARD G9
Abstract 59: Prognostic significance of circulating tumor cells in patients with gastric cancer: Epithelial mesenchymal transition and perioperative kinetics.
First Author: Yui Ishiguro, M.D.


BOARD G10
Abstract 60: Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers.
First Author: Michael Cerniglia, BS


BOARD G11
Abstract 61: Proteomic analysis to identify markers for response to treatment in esophageal cancer.
First Author: Oran Zlotnik, MD


BOARD G13
Abstract 63: Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.
First Author: Alberto Puccini, MD


BOARD G14
Abstract 64: A novel patient derived orthotopic xenograft model of gastro-esophageal junction cancer: Key platform for translational discoveries.
First Author: Omkara Veeranki, DVM, PhD


BOARD G15
Abstract 65: Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).
First Author: Daniel Catenacci, MD


BOARD G16
Abstract 66: MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).
First Author: Filippo Pietrantonio, MD


BOARD G17
Abstract 67: Activated interferon-γ (IFN-γ) pathway associated with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC).
First Author: Jhe-Cyuan Guo, MD


BOARD G18
Abstract 68: Examining the effects of BET, HDAC2, and EZH2 inhibition on esophageal adenocarcinoma (EAC) cell line proliferation.
First Author: Kleovoulos Kofonikolas


BOARD G19
Abstract 69: Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab.
First Author: Justin Moser, MD


BOARD G20
Abstract 70: KRAS amplification and mutation are independent events in gastroesophageal adenocarcinomas (GEA).
First Author: Russell Madison, BA


BOARD H1
Abstract 71: Elucidating the pathogenesis of esophageal adenocarcinoma through meta-analysis of public data.
First Author: Kamal Khorfan, MD


BOARD H2
Abstract 72: FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.
First Author: Samuel Klempner, MD


BOARD H3
Abstract 73: Mortality and glycemic control among patients with gastric and esophageal cancer and diabetes mellitus.
First Author: Nina Karlin, MD, FACP


BOARD H4
Abstract 74: Preprocedural prediction of non-curative endoscopic submucosal dissection for early gastric cancer.
First Author: Cheol Woong Choi


BOARD H5
Abstract 75: A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
First Author: Manish Shah, MD, FASCO


BOARD H6
Abstract 76: Endoscopic features of submucosal invasion in undifferentiated type early gastric cancer sized less than 2 cm without ulceration.
First Author: Su Jin Kim


BOARD H7
Abstract 77: Long-term outcome of laparoscopic versus open total gastrectomy for advanced gastric cancer: A propensity score-matched analysis.
First Author: Hayemin Lee, MD


BOARD H8
Abstract 78: The impact of neoadjuvant chemoradiation versus chemotherapy on short and long-term outcomes among gastric carcinoma patients.
First Author: Basem Azab, MD


BOARD H9
Abstract 79: The value of lymphadenectomy in esophageal cancer after neoadjuvant chemoradiation.
First Author: Basem Azab, MD


BOARD H10
Abstract 80: Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G).
First Author: Kensei Yamaguchi, MD


BOARD H11
Abstract 81: A comparison of elderly versus nonelderly patients in the CRITICS gastric cancer trial.
First Author: Astrid Slagter, MSc


BOARD H12
Abstract 82: Prognostic factor analysis in third-line chemotherapy for elderly patients with metastatic gastric cancer.
First Author: Hiroko Hasegawa


BOARD H13
Abstract 83: A retrospective analysis of third-line treatment in advanced gastric cancer.
First Author: Yasunobu Ishizuka


BOARD H14
Abstract 84: Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer.
First Author: Kyoko Kato


BOARD H15
Abstract 85: Prognostic Nutritional Index as a predictive factor of survival in patients with gastric cancer in a Mexican population.
First Author: Marytere Herrera, MD


BOARD H16
Abstract 86: Prospective evaluation of a developed S-1 dosage formula based on renal function.
First Author: Takuro Mizukami, MD, PhD


BOARD H17
Abstract 87: Feasibility of endoscopic resection in early gastric cancer with lymphovascular invasion.
First Author: Jun Haeng Lee


BOARD H18
Abstract 88: Clinical outcomes in patients undergoing multiple self-expandable metallic stent placement by stent in stent technique for malignant gastric outlet obstruction.
First Author: Jinwon MO, MD


BOARD H19
Abstract 89: Nutrition and exercise patterns in survivors of esophageal and gastroesophageal junction (EGEJ) cancers.
First Author: Rishi Jain, MD, MS


BOARD H20
Abstract 90: Multicenter prospective observational study of QoL after palliative surgery for patients with bowel obstruction caused by peritoneal dissemination of gastric cancer.
First Author: Yuichi Ito, MD, PhD


BOARD J1
Abstract 91: Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).
First Author: Mohamedtaki Tejani, MD


BOARD J2
Abstract 92: Downstaging and survival after neoadjuvant approaches to gastroesophageal junction adenocarcinoma.
First Author: Michael Xiang, MD, PhD


BOARD J3
Abstract 93: Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer.
First Author: Takaki Yoshikawa, MD, PhD


BOARD J4
Abstract 94: Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients.
First Author: Kazuhiro Nishikawa, MD, PhD


BOARD J5
Abstract 95: Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): a randomized, double-blind, multicenter phase II trial.
First Author: Jing Huang, MD


BOARD J6
Abstract 96: Predictors of distress among individuals with gastric cancer.
First Author: Julie Olson, PhD


BOARD J7
Abstract 97: Locally advanced gastric cancer (LAGC): Does histology suggest strategy in PAN-cancer Era?
First Author: Ina Valeria Zurlo, MD


BOARD J9
Abstract 99: Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors.
First Author: Taroh Satoh, MD, PhD


BOARD J10
Abstract 100: Survival outcomes comparable between endoscopic resection and surgical resection for T1b esophageal adenocarcinoma.
First Author: Samit Datta, MD


BOARD J11
Abstract 101: The potential drug cost impact of nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) in Canada.
First Author: Kiran Virik, MD, FRACP, FRCPC


BOARD J12
Abstract 102: Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).
First Author: Mayur Amonkar, PhD


BOARD J13
Abstract 103: Survival impact of the response at twelve weeks in patients with advanced gastric cancer received first-line chemotherapy.
First Author: Motoko Arakaki, MD


BOARD J14
Abstract 104: Influence of radiation field on safety and efficacy for stage II/III esophageal cancer treated with definitive chemoradiotherapy: An exploratory analysis of JCOG0909.
First Author: Azusa Komori


BOARD J15
Abstract 105: Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).
First Author: Lynn Huynh, MPH, MBA, DrPH


BOARD J16
Abstract 106: Efficacy of three-drug induction chemotherapy followed by preoperative chemoradiation in patients with localized gastric adenocarcinoma (GAC).
First Author: Dilsa Mizrak Kaya, MD


BOARD J17
Abstract 107: The impact of muscle mass loss after esophagectomy for esophageal cancer on prognosis.
First Author: Yota Shimoda, None


BOARD J18
Abstract 108: Anatomical topography of the tumor is related to prognostic survival in adenocarcinoma of esophagogastric junction?: Multivariable analysis.
First Author: Flavio Takeda


BOARD K1
Abstract 109: Role of volume reduction gastrectomy according to tumor location in patients with gastric cancer with a single noncurable factor: REGATTA trial (JCOG0705/KGCA01) supplementary analysis.
First Author: Masanori Terashima, MD, PhD


BOARD K2
Abstract 110: Subgroup analysis of JCOG0501 phase III study to confirm superiority of additional neoadjuvant chemotherapy with S-1 plus cisplatin to D2 gastrectomy with S-1 adjuvant chemotherapy for resectable type IV or large type III gastric cancer.
First Author: Hitoshi Katai


BOARD K3
Abstract 111: Endoscopic submucosal dissection versus surgery for undifferentiated-type early gastric cancer: A meta-analysis.
First Author: Byung-Wook Kim, MD, PhD


BOARD K4
Abstract 112: The efficacy of splenic hilar lymph node dissection in advanced gastric cancer.
First Author: Tetsuro Toriumi, M.D.


BOARD K5
Abstract 113: Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A retrospective real world study.
First Author: Yang Chen, M.D., Ph.D


BOARD K6
Abstract 114: Endoscopic submucosal dissection using a novel endoscopic articulating knife for clinical staging of early esophageal neoplasia.
First Author: Juan Genere, MD


BOARD K7
Abstract 115: A retrospective analysis of neoadjuvant chemotherapy followed by surgery or definitive chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma.
First Author: Hiroshi Nakatsumi, MD, PhD


BOARD K8
Abstract 116: A phase I/Ib study of crenolanib with ramucirumab (RAM)/paclitaxel (PTX) as second-line therapy (2L tx) for advanced esophagogastric adenocarcinoma (EGA).
First Author: Megan Greally


BOARD K9
Abstract 117: Systemic chemo (CTX) plus surgery and intraperitoneal (IP) CTX for patients (pts) with gastric cancer (GC) and peritoneal carcinomatosis (PC).
First Author: Megan Greally


BOARD K10
Abstract 118: Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab.
First Author: Carrie Brachmann


BOARD K11
Abstract 119: Impact of radiation dose during neoadjuvant chemoradiation on postoperative complications in esophageal (EC) and gastroesophageal junction cancers (GEJC).
First Author: Noah Kastelowitz, MD, PhD


BOARD K12
Abstract 120: The preventive effect of neoadjuvant therapy on poor long-term outcomes of postoperative complications in patients with esophageal squamous cell carcinoma: A retrospective cohort study.
First Author: Masashi Takeuchi


BOARD K13
Abstract 121: Pre-treatment pulmonary function testing as a predictor of cardiopulmonary toxicity in esophageal cancer patients treated with trimodality therapy.
First Author: Na Smith, MD, PhD


BOARD K14
Abstract 122: The impact of infectious complications on long-term prognosis after curative resection for gastric cancer.
First Author: Yukio Maezawa, MD


BOARD K15
Abstract 123: Comparison between S-1 monotherapy and S-1 plus cisplatin as postoperative chemotherapy after R0 resection for stage IV gastric cancer patients with oligometastasis: A multicenter retrospective study.
First Author: Koshi Kumagai, MD, PhD


BOARD K16
Abstract 124: The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer.
First Author: Masahiko Aoki, MD


BOARD K17
Abstract 125: Gls-010, a novel anti-PD-1 mAb in Chinese advanced gastrointestinal tumor: Result of a phase Ib clinical trial.
First Author: Shen Lin, MD


BOARD K18
Abstract 126: Hyperprogressive disease (HPD) during nivolumab (Nivo) or irinotecan (IRI) as salvage line in patients with metastatic gastric cancer (MGC).
First Author: Naotoshi Sugimoto, MD, PhD


BOARD K19
Abstract 127: Neoadjuvant treatment in patients with locally advanced gastric cancer.
First Author: Mahmut Gumus


BOARD K20
Abstract 128: Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).
First Author: Ian Chau, MD


BOARD L1
Abstract 129: Phase I/II study of ramucirumab plus nivolumab in patients in second line treatment for advanced gastric adenocarcinoma (NivoRam study).
First Author: Hiroki Hara, MD


BOARD L2
Abstract 130: Endoscopic intratumoral injection of OBP-301 (telomelysin) with radiotherapy in esophageal cancer patients unfit for standard treatments.
First Author: Shunsuke Tanabe, MD, PhD


BOARD L3
Abstract 131: A multicenter study of trimodality therapy for patients 75 years and older with esophageal cancer.
First Author: Niamh McDonnell


BOARD L4
Abstract 132: Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy containing paclitaxel for advanced gastric cancer.
First Author: Ryo Otsuka, BPharm


BOARD L5
Abstract 133: Prognostic value of nutritional status for esophageal cancer patients undergoing neoadjuvant therapy and resection.
First Author: Sabrina Saeed


BOARD L6
Abstract 134: Impact of double-flap technique for reconstruction after proximal gastrectomy.
First Author: Kazuki Asanuma, MD


BOARD L7
Abstract 135: Oncologic outcomes after laparoscopic and open distal gastrectomy for advanced gastric cancer: A propensity score matching analysis.
First Author: Yoona Chung


BOARD L8
Abstract 136: Gastric cancer liver metastasis: Optimal management for oligo-metastatic disease.
First Author: Hiromichi Ito, MD, FACS


BOARD L9
Abstract 137: Phase 1b study of andecaliximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma.
First Author: Kensei Yamaguchi, MD


BOARD L10
Abstract 138: Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
First Author: Jian Li, MD


BOARD L11
Abstract 139: Safety of laparoscopic total gastrectomy with splenectomy for upper third advanced gastric cancer.
First Author: Eigo Akimoto


BOARD L12
Abstract 140: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
First Author: Yung-Jue Bang, MD, PhD


BOARD L13
Abstract 141: Long-term outcome of preoperative docetaxel with cisplatin plus S-1 therapy for advanced gastric cancer with extensive nodal metastasis (JCOG1002).
First Author: Shinji Morita, MD, PhD


BOARD L14
Abstract 142: Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer.
First Author: Ronan Kelly, MBA, MD


BOARD L15
Abstract 143: Impact of antibiotic use on response to treatment with immune checkpoint inhibitors.
First Author: Uqba Khan, MD


BOARD L16
Abstract 144: A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (OGSG 1106).
First Author: Hiroki Yukami, MD


BOARD L17
Abstract 145: Clinical impact of newly developed sarcopenia after surgical resection for gastric cancer.
First Author: Beom Jin Kim, M.D.,Ph.D.


BOARD L18
Abstract 146: Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).
First Author: Dae Ho Lee, MD, PhD


BOARD L19
Abstract 147: Predictors of lymphopenia in esophageal cancer patients receiving photon or proton radiation therapy: A dosimetric analysis.
First Author: David Routman, MD


BOARD L20
Abstract 148: Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.
First Author: Jean-Philippe Metges, MD


BOARD M1
Abstract 149: Prognostic and predictive factors after failure of two drug lines for metastatic gastric adenocarcinomas: A French retrospective study.
First Author: Benjamin Boussac, MD


BOARD M2
Abstract 150: The combination of the changes and the value of neutrophil-to-lymphocyte ratio is useful for prediction of response for advanced gastric cancer treated with nivolumab: A multicenter retrospective study.
First Author: Takatsugu Ogata


BOARD M3
Abstract 151: Simulation study on regionalization of esophagectomy using data of 27,576 patients with esophageal malignant tumor.
First Author: Tatsuto Nishigori


BOARD M4
Abstract 152: Predictive biomarkers for the efficacy of nivolumab as ≥ third-line therapy in patients with advanced gastric cancer (AGC): From a subset analysis of ATTRACTION-2 phase III trial.
First Author: Jwa Kim, M.D.


BOARD M5
Abstract 153: The effect of IMRT on acute toxicity in patients with gastric cancer treated with preoperative chemoradiation.
First Author: Shalini Moningi, MD


BOARD M6
Abstract 154: Three different chemotherapeutic regimens as a postoperative adjuvant chemotherapy for curatively resected gastric cancer: A retrospective analysis.
First Author: Shen Zhao, ABFT


BOARD M7
Abstract 155: Surgical outcomes of laparoscopic transhiatal lower mediastinal lymphadenectomy for seiwert type II adenocarcinoma of the esophagogastric junction.
First Author: Masanori Tokunaga


BOARD M8
Abstract 156: The real-world data in patients with advanced gastric cancer treated with ramucirumab combination chemotherapy.
First Author: Akie Kimura, MD


BOARD M9
Abstract 157: Timing after neoadjuvant therapy predicts mortality in patients undergoing esophagectomy.
First Author: Taylor Maramara, MS


BOARD M10
Abstract 158: Gastric adenocarcinoma prognosis in a multiracial population.
First Author: Jared Acoba, MD


BOARD M11
Abstract 159: Which is the best procedure for the treatment of gastric cancer in the upper stomach?
First Author: Reo Sato


BOARD M12
Abstract 160: Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection.
First Author: Kabsoo Shin, MD


BOARD M13
Abstract 161: Exploration of patients with gastric cancer who benefit from apatinib: An updated real-world study.
First Author: Guo-ping Sun


BOARD M14
Abstract 162: Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).
First Author: Di Jiang, MD, FRCPC


BOARD M15
Abstract 163: Characteristics of long-term survivors in stage III gastric cancer patients.
First Author: Youjin Jang


BOARD M16
Abstract 164: Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.
First Author: Lucy Ma


BOARD M17
Abstract 165: The association of 5FU-based chemotherapy with pathological response or survival compared to carbo/taxol with locally advanced resectable esophageal cancer.
First Author: Mohammed Al-Jumayli, MD


BOARD M18
Abstract 166: Survival benefit of gastric resection in the setting of metastatic gastric cancer.
First Author: Trang Nguyen


BOARD M19
Abstract 167: Impact of preoperative treatment with chemoradiotherapy or chemotherapy in patients with locally advanced or irresecable gastric cancer (LAGC).
First Author: C Diaz Romero


BOARD M20
Abstract 168: Tumor regression grade in gastric cancer after preoperative therapy.
First Author: Naruhiko Ikoma, MD, MS


BOARD N2
Abstract 170: Impact of clostridium difficile infection on gastrointestinal malignancies.
First Author: Stuthi Perimbeti, MD MPH


BOARD N3
Abstract 171: Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.
First Author: Kirsty Taylor, MBBCh, MRCP


BOARD N4
Abstract 172: Utility of radiation after neoadjuvant chemotherapy for surgically resectable esophageal cancer.
First Author: Francis Macedo, MD


BOARD N5
Abstract TPS173: A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.
First Author: Fortunato Ciardiello, MD


BOARD N6
Abstract TPS174: Multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for second line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
First Author: Nadja Meindl-Beinker, PhD


BOARD N7
Abstract TPS175: A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) [NCT03641313].
First Author: Satya Das, MD


BOARD N8
Abstract TPS176: A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.
First Author: Ursula Wiedermann, MD, PhD


BOARD N9
Abstract TPS177: A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2 positive advanced gastric cancer (Ni-HIGH study).
First Author: Daisuke Takahari, MD, PhD


BOARD N10
Abstract TPS178: REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progREssiVe dIsease of niVolumab (NIV) thErapy for metastatic gastric cancer (mGC).
First Author: Yukiya Narita, MD


BOARD N11
Abstract TPS179: bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).
First Author: Yoshiaki Nakamura, MD, PhD


BOARD N12
Abstract TPS180: A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
First Author: Kohei Shitara, MD


BOARD N13
Abstract TPS181: Phase I/II trial of perioperative avelumab in combination with chemoradiation in the treatment of stage II/III resectable esophageal cancer.
First Author: Nataliya Uboha, MD, PhD


BOARD N15
Abstract TPS183: HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.
First Author: Atsushi Ishiguro, MD, PhD


BOARD N16
Abstract TPS184: Multicenter prospective randomized controlled trial of comparing laparoscopic proximal gastrectomy and laparoscopic total gastrectomy for upper third early gastric cancer (KLASS-05).
First Author: Do Joong Park, M.D., Ph.D.